Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | DGKA | P23743 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19861337 | 0.92 | CYP1A2 (0.50) | CYP1A2NR1I2PGRADORA3PTGS2 | |
| SCHEMBL8165697 | 0.83 | CYP1A2 (0.57) | CYP1A2NR1I2PGRADORA3PTGS2 | |
| SCHEMBL11591296 | 0.83 | CYP1A2 (0.48) | CYP1A2NR1I2PGRADORA3PTGS2 | |
| SCHEMBL19861446 | 0.83 | DGKA (0.53) | CYP1A2GAAALDH1A1TSHRDGKA | |
| SCHEMBL21015257 | 0.82 | CYP1A2 (0.52) | CYP1A2NR1I2PGRADORA3PTGS2 | |
| SCHEMBL20076395 | 0.82 | MAPT (0.45) | ALDH1A1TDP1CYP3A4TSHRDGKA | |
| SCHEMBL27526995 | 0.82 | CYP1A2 (0.55) | CYP1A2NR1I2PGRADORA3PTGS2 | |
| SCHEMBL12585170 | 0.82 | TSHR (0.56) | ALDH1A1TSHRHSD17B10L3MBTL1KMT2A | |
| SCHEMBL26711435 | 0.81 | CYP1A2 (0.46) | CYP1A2NR1I2PGRADORA3PTGS2 | |
| SCHEMBL3505416 | 0.80 | TSHR (0.60) | CYP1A2NR1I2PGRADORA3PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647747-B2 | Cyclosporin derivatives and uses thereof | S&T GLOBAL INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20180105558-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. | 2018-04-19 | — | — | US | disclosed |
| CN-103274959-B | Synthetic method of cooling agent N-, 2, 3-trimethyl-2-isopropyl butyrylamide | UNIV ANHUI SCIENCE & TECH | 2015-04-08 | — | — | CN | disclosed |
| CN-103274959-A | Synthetic method of cooling agent N-, 2, 3-trimethyl-2-isopropyl butyrylamide | UNIV ANHUI SCIENCE & TECH | 2013-09-04 | — | — | CN | disclosed |
| WO-2009061854-A2 | MULTIFUNCTIONAL DEGRADABLE NANOPARTICLES WITH CONTROL OVER SIZE AND FUNCTIONALITIES | VANDERBILT UNIVERSITY (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647747-B2 | Cyclosporin derivatives and uses thereof | FKBP5, FKBP1B, MALT1 | CYP1A2 805/4885NR1I2 1329/4885PGR 2172/4885 |
| US-20180105558-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | FKBP1B, MALT1, FKBP5 | CYP1A2 1223/4885NR1I2 1275/4885PGR 2586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.